Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens
Authors
Keywords
-
Journal
HIV MEDICINE
Volume 18, Issue 1, Pages 21-32
Publisher
Wiley
Online
2016-06-30
DOI
10.1111/hiv.12388
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1
- (2014) Jeffrey L. Lennox et al. ANNALS OF INTERNAL MEDICINE
- Effectiveness of efavirenz compared with ritonavir-boosted protease inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/ml
- (2014) Arkaitz Imaz et al. ANTIVIRAL THERAPY
- Reliability and Clinical Relevance of the HIV-1 Drug Resistance Test in Patients With Low Viremia Levels
- (2014) Maria Mercedes Santoro et al. CLINICAL INFECTIOUS DISEASES
- Antiretroviral Treatment of Adult HIV Infection
- (2014) Huldrych F. Günthard et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy of a reduced dose of darunavir/ritonavir in a cohort of antiretroviral-naive and -experienced HIV-infected patients: a medium-term follow-up
- (2014) M. Lanzafame et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay
- (2014) C. Charpentier et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy
- (2014) Antonio Di Biagio et al. JOURNAL OF MEDICAL VIROLOGY
- Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
- (2014) Bonaventura Clotet et al. LANCET
- Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO
- (2014) Jean-Michel Molina et al. Journal of the International AIDS Society
- Impact of pre-therapy viral load on virological response to modern first-line HAART
- (2013) Maria Mercedes Santoro et al. ANTIVIRAL THERAPY
- High rate of virologic suppression with darunavir/ritonavir plus optimized background therapy among highly antiretroviral-experienced HIV-infected patients: results of a prospective cohort study in São Paulo, Brazil
- (2013) José Ernesto Vidal et al. Brazilian Journal of Infectious Diseases
- Virologic and immunologic effectiveness of darunavir-based salvage therapy in HIV-1-infected adults in a Brazilian clinical practice setting: results of a multicenter and retrospective cohort study
- (2013) Karina Mota Ribeiro et al. Brazilian Journal of Infectious Diseases
- Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial
- (2013) M Sension et al. HIV MEDICINE
- Safety and durability in a cohort of HIV-1 positive patients treated with once and twice daily darunavir-based therapy (SCOLTA Project)
- (2012) Barbara Menzaghi et al. BIOMEDICINE & PHARMACOTHERAPY
- Week 96 Efficacy, Virology and Safety of Darunavir/r Versus Lopinavir/r in Treatment-Experienced Patients in TITAN
- (2012) Denes Banhegyi et al. CURRENT HIV RESEARCH
- Darunavir: a nonpeptidic protease inhibitor for antiretroviral-naive and treatment-experienced adults with HIV infection
- (2012) Jaime Robertson et al. EXPERT OPINION ON PHARMACOTHERAPY
- Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial
- (2012) C Orkin et al. HIV MEDICINE
- Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients
- (2011) Pedro Cahn et al. AIDS
- Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals
- (2010) A. Imaz et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance
- (2009) Annemarie M.J. Wensing et al. ANTIVIRAL RESEARCH
- Effect of HIV‐1 Subtype on Virologic and Immunologic Response to Starting Highly Active Antiretroviral Therapy
- (2009) Anna Maria Geretti et al. CLINICAL INFECTIOUS DISEASES
- Raltegravir, Etravirine, and Ritonavir-Boosted Darunavir: A Safe and Successful Rescue Regimen for Multidrug-Resistant HIV-1 Infection
- (2009) Arkaitz Imaz et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Magnetic-silica based nucleic acid extraction for Human Immunodeficiency Virus Type-1 drug-resistance testing in low viremic patients
- (2009) Maria Grazia Milia et al. JOURNAL OF CLINICAL VIROLOGY
- Resistance Profile of Darunavir: Combined 24-Week Results from the POWER Trials
- (2008) Sandra de Meyer et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now